| Symbol | APLS |
|---|---|
| Name | APELLIS PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 FIFTH AVENUE, WALTHAM, Massachusetts, 02451, United States |
| Telephone | +1 617 977-5700 |
| Fax | — |
| — | |
| Website | https://www.apellis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade. Additional info from NASDAQ: |
Sullivan Timothy Eugene 🟡 adjusted position in 0 shares of Apellis Pharmaceuticals, Inc. (APLS) Transaction Date: Apr 17, 2026 | Filing ID: 163917
Read moreApellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
Read moreNew Form SC 14D9 - Apellis Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-14 <b>AccNo:</b> 0001193125-26-153887 <b>Size:</b> 1 MB
Read moreNew Form SC TO-T - Apellis Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-14 <b>AccNo:</b> 0001193125-26-153814 <b>Size:</b> 1 MB
Read moreDirector O'Brien Stephanie Monaghan 🟢 acquired 5.8K shares of Apellis Pharmaceuticals, Inc. (APLS) Transaction Date: Apr 06, 2026 | Filing ID: 000099
Read moreNew Form SC TO-C - Apellis Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0000950157-26-000483 <b>Size:</b> 3 MB
Read moreNew Form SCHEDULE 13G/A - Apellis Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0000902219-26-000117 <b>Size:</b> 15 KB
Read moreNew Form 3 - Apellis Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0000950157-26-000479 <b>Size:</b> 9 KB
Read moreNew Form SCHEDULE 13D - Apellis Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0000950157-26-000478 <b>Size:</b> 764 KB
Read moreNew Form SC14D9C - Apellis Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0001193125-26-143698 <b>Size:</b> 96 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07020832 | A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults … | Phase3 | Delayed Graft Function | Recruiting | 2026-02-01 | 2028-08-01 | ClinicalTrials.gov |
| NCT07213960 | A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulo… | Phase2 | FSGS | Not_Yet_Recruiting | 2025-12-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT07214740 | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe | Phase3 | Geographic Atrophy Secondary to Age-related Macular Degeneration | Completed | 2025-10-24 | 2025-12-12 | ClinicalTrials.gov |
| NCT07215390 | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluat… | Phase2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | Recruiting | 2025-06-23 | 2027-11-01 | ClinicalTrials.gov |
| NCT06161584 | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate… | — | Geographic Atrophy | Active_Not_Recruiting | 2023-09-28 | 2027-06-01 | ClinicalTrials.gov |
| NCT05809531 | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-… | Phase3 | C3G | Active_Not_Recruiting | 2023-05-29 | 2027-07-01 | ClinicalTrials.gov |
| NCT06241625 | Virtual Reality Based Vision Test in Patients With AMD | Na | Age-Related Macular Degeneration | Unknown | 2022-10-20 | 2024-07-01 | ClinicalTrials.gov |
| NCT05148299 | A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Mic… | Phase2 | Transplant-Associated Thrombotic Microangiopathy | Completed | 2022-02-01 | 2024-12-08 | ClinicalTrials.gov |
| NCT05067127 | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients … | Phase3 | C3G | Completed | 2021-11-12 | 2025-01-14 | ClinicalTrials.gov |
| NCT04572854 | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Rec… | Phase2 | C3G | Completed | 2021-09-07 | 2026-01-20 | ClinicalTrials.gov |
| NCT04901936 | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemogl… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Recruiting | 2021-02-04 | 2028-12-01 | ClinicalTrials.gov |
| NCT04402060 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | Phase1 | COVID | Completed | 2020-05-28 | 2021-02-13 | ClinicalTrials.gov |
| NCT04085601 | A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With P… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2019-08-27 | 2021-06-23 | ClinicalTrials.gov |
| NCT03777332 | Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With G… | Phase1 | Geographic Atrophy | Completed | 2018-11-05 | 2021-04-01 | ClinicalTrials.gov |
| NCT03525613 | A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With S… | Phase3 | Geographic Atrophy | Completed | 2018-08-31 | 2022-06-28 | ClinicalTrials.gov |
| NCT03525600 | Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sha… | Phase3 | Geographic Atrophy | Completed | 2018-08-31 | 2022-06-20 | ClinicalTrials.gov |
| NCT03531255 | Pegcetacoplan Long Term Safety and Efficacy Extension Study | Phase3 | PNH | Active_Not_Recruiting | 2018-08-27 | 2026-07-01 | ClinicalTrials.gov |
| NCT03593200 | A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcu… | Phase2 | PNH | Completed | 2018-08-16 | 2019-10-22 | ClinicalTrials.gov |
| NCT03500549 | Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal … | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2018-06-14 | 2020-08-13 | ClinicalTrials.gov |
| NCT02503332 | Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy | Phase2 | Geographic Atrophy | Completed | 2015-09-24 | 2018-01-17 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pegcetacoplan | Other | Phase PHASE2 | C3G | COMPLETED | NCT04572854 |
| Pegcetacoplan | Other | Phase PHASE2 | C3G | COMPLETED | NCT04572854 |
| Pegcetacoplan | Other | Phase PHASE2 | C3G | COMPLETED | NCT04572854 |
| Pegcetacoplan | Other | Phase PHASE2 | C3G | COMPLETED | NCT04572854 |
| Pegcetacoplan | Other | Phase PHASE2 | C3G | COMPLETED | NCT04572854 |
| Pegcetacoplan | Other | Phase PHASE2 | C3G | COMPLETED | NCT04572854 |
| Pegcetacoplan | Other | Phase PHASE2 | C3G | COMPLETED | NCT04572854 |
| Pegcetacoplan | Other | Phase PHASE2 | C3G | COMPLETED | NCT04572854 |
| AP-472 | DRUG | Phase PHASE2 | Parkinson Disease | RECRUITING | NCT07432958 |
| Placebo, Syfovre | OTHER | Phase PHASE2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | RECRUITING | NCT07215390 |
| APL-3007, pegcetacoplan (APL-2) | DRUG | Phase PHASE2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | RECRUITING | NCT07215390 |
| APL-2, Pegcetacoplan | DRUG | Phase PHASE3 | Geographic Atrophy Secondary to Age-related Macular Degeneration | COMPLETED | NCT07214740 |
| APL2 | DRUG | Phase PHASE2 | FSGS | NOT_YET_RECRUITING | NCT07213960 |
| Placebo | OTHER | Phase PHASE2 | Parkinson Disease | RECRUITING | NCT07432958 |
| Pegcetacoplan (APL-2) | DRUG | Phase PHASE2 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04579666 |
| Vehicle Control | OTHER | Phase PHASE1 | COVID | COMPLETED | NCT04402060 |
| APL-9 | DRUG | Phase PHASE1 | COVID | COMPLETED | NCT04402060 |
| PEGCETACOPLAN (APL-2) | DRUG | Phase PHASE3 | Geographic Atrophy Secondary to Age-related Macular Degeneration | COMPLETED | NCT04770545 |
| Soliris | DRUG | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT03500549 |
| APL-2 | DRUG | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04085601 |
| Sham Procedure | OTHER | Phase PHASE3 | Geographic Atrophy | COMPLETED | NCT03525613 |
| Pegcetacoplan | DRUG | Phase PHASE3 | Delayed Graft Function | RECRUITING | NCT07020832 |